Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study evaluate the regional (neck) nodal control of durvalumab in combination with RT
restricted to the primary tumor and the immediately adjacent nodal level (i.e. without
prophylactic neck irradiation) in N0 patients with SCCHN.